Announcement: Aurelia Bioscience has been acquired by Charnwood Molecular.

Share this

During PROTAC development various assays are required to inform and progress the design-make-test cycle. PROTAC’s have been developed to BRD4 – a member of the BET (bromodomain and extra-terminal) family.

At Charnwood Molecular we have used cell-based and biophysical techniques to investigate the BRD4-targeting PROTAC ‘dBET6’ to elucidate a binding mechanism, confirm proteasomal degradation and monitor its impact on cellular behaviour.

In this webinar we demonstrate a set of orthogonal techniques used to probe BRD4 PROTAC activity that we might typically implement in a PROTAC development cascade to build confidence in target depletion and associated biological validation.

Find out more and register your place here.